tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Amylyx price target raised to $16 from $12 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Amylyx (AMLX) to $16 from $12 and keeps a Buy rating on the shares after the company announced the Phase 3 LUCIDITY trial of avexitide is currently underway with the topline data expected in the first half of 2026.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1